An adult reads beside a window with a closed laptop on a nearby table.

What Addiction Treatment Research Is Studying | NM

Addiction treatment research examines new ways to address substance use, cravings, and related health problems. NIDA describes work on medicines, brain stimulation, immune approaches, and psychedelic drugs used with psychotherapy. These approaches target different problems, and being studied does not make an approach established care.

The distinction starts with purpose: what is a proposed treatment intended to change? The broader explanation of how addiction treatments work describes established targets such as withdrawal, cravings, and learned behavior. Research builds on those needs without making every new approach ready for practice. For an adult considering care or a concerned loved one, understanding the targets can make unfamiliar terms less confusing. It also puts medication questions in outpatient substance use care in context: an interesting scientific idea and an appropriate treatment decision are different things.

Written by Tim Francis, SUD Content Specialist. Tim is a nonclinical author. This guide supports discussion with qualified professionals.

What problems is addiction treatment research trying to solve?

Addiction treatment research aims to expand how care addresses substance use, cravings, withdrawal, and related health problems. These targets connect with established addiction treatment mechanisms and medication decisions in outpatient care, while also addressing substance use disorders for which approved medicines are still missing.

According to NIDA's treatment overview, substance use disorders are complex, treatable chronic medical conditions. Treatment can help people stop or reduce use, prevent a return to use, and improve functioning in family, work, and community life. Research therefore has several connected goals rather than one universal target.

  • Reduce withdrawal symptoms and cravings.
  • Make substance use less appealing.
  • Address related problems, including sleep disturbances.
  • Expand treatment options across different substance use disorders.

These goals overlap, but they are not interchangeable. Reducing a physical symptom is different from changing a learned response to a stressful situation. Changing a drug's effects is different from helping someone maintain relationships or meet daily responsibilities. A proposed treatment may address one part of this picture without addressing every need.

NIDA also describes medical and mental health conditions that can occur alongside substance use disorders. That helps explain why research cannot focus only on the substance itself. The useful question is how an approach might fit the person's connected health needs, not whether one discovery could replace all other care.

Why does addiction treatment research study new medications and existing medicines such as GLP-1 agonists?

Medication research seeks additional ways to reduce substance use, cravings, withdrawal, or related symptoms. It includes developing new compounds and studying medicines already used for other conditions. Understanding what addiction medicines are intended to change helps separate these research goals from individual medication decisions in outpatient care.

One reason for this work is a gap in existing options. NIDA identifies approved medications for opioid use disorder, alcohol use disorder, and smoking cessation. It also describes research to develop compounds for stimulant and cannabis use disorders, for which FDA-approved treatment medicines do not yet exist.

A lack of approved medication does not mean a disorder is untreatable. Behavioral treatments remain part of care. It means researchers are trying to add another kind of treatment tool, rather than assuming that one medicine can address every substance use disorder.

NIDA names GLP-1 agonists among its emerging research areas and gives semaglutide, a medicine used for diabetes and weight management, as an example. Studying an existing medicine for a different condition means investigating a new treatment purpose. Its familiar name or established use elsewhere does not establish an addiction-treatment role.

The same boundary applies to proposed mechanisms. Knowing that a medicine affects a biological process does not establish how it should be used for substance use care. NIDA's overview identifies GLP-1 medicines as a research direction; it does not provide a basis for choosing one as addiction treatment.

This distinction allows room for scientific interest without turning that interest into prescribing advice. An emerging possibility should not prompt a self-directed change to an existing prescription or replacement of ongoing care.

What is brain stimulation intended to change in addiction treatment research?

Brain stimulation research examines ways to influence brain circuitry involved in addiction and other brain disorders. Its proposed target differs from a medicine's action, although both concern biological processes. Understanding treatment mechanisms and checking recovery health claims helps keep a proposed circuit-level effect separate from an established treatment benefit.

NIDA uses the term neuromodulation for this research area. In plain language, the aim is to change activity in brain circuitry. NIDA names several approaches, including:

  • Deep brain stimulation.
  • Low-intensity focused ultrasound.
  • Transcranial magnetic stimulation, also called TMS.

NIDA describes focused ultrasound and TMS as noninvasive approaches. These names identify different technologies, not one interchangeable treatment. Their inclusion in the same research category does not establish that they have the same role or evidence for every substance use disorder.

An especially useful distinction concerns approval for a specific purpose. NIDA states that TMS is FDA-approved for smoking cessation and is being studied for other substance use disorders. A smoking-cessation approval does not establish effectiveness for opioid, alcohol, stimulant, or cannabis use disorders.

Words such as “reset” can also create unrealistic expectations if they suggest that addiction has a single switch. NIDA discusses brain circuitry alongside medicines, behavioral therapies, and care for related health conditions. A biological target should be understood within that broader picture, rather than as a promise to erase a person's history or remove every recovery challenge.

What are vaccines and monoclonal antibodies intended to do in addiction research?

NIDA describes vaccines and monoclonal antibodies as research approaches intended to recruit the immune system to keep drugs from entering the brain. This target differs from established treatments addressing cravings and behavior. When evaluating addiction treatment claims, a proposed immune effect should not be mistaken for an established cure.

In its treatment research overview, NIDA gives vaccines against cocaine and opioids as examples. Here, the word vaccine describes a drug-targeting research concept. It does not mean that routine vaccination against addiction is established care.

The intended point of action matters. These approaches concern a drug's access to the brain. That is a different task from helping someone recognize a cue, change a routine, manage stress, or rebuild daily functioning. Even an approach aimed directly at drug exposure should not be described as automatically resolving those other needs.

Vaccines and monoclonal antibodies also should not be collapsed into one product category. NIDA lists them within a shared immune-based research direction, but that broad description does not establish that every approach has the same properties or possible use.

The practical meaning is narrower than a headline about an “addiction vaccine” might suggest. NIDA identifies an intended biological strategy and examples under investigation. That description does not establish routine availability, suitability for a particular person, or a replacement for continuing substance use care. The research target is specific; the person's treatment needs may be much broader.

What does NIDA describe about psychedelic drugs being studied with psychotherapy?

NIDA describes research involving psychedelic drugs such as psilocybin and dissociative drugs such as ketamine, used with psychotherapy in clinical settings. The combination and setting matter. Reading recovery health claims carefully and keeping medication decisions within qualified care prevents a research description from becoming an endorsement of unsupervised use.

The NIDA overview presents these substances as an area of continuing investigation. It distinguishes psychedelic drugs from dissociative drugs rather than treating all altered-state substances as one medicine. Naming a substance in this research context does not establish that every substance in either category has the same treatment role.

Psychotherapy is part of the description, not an incidental detail. NIDA discusses the drugs in combination with psychotherapy in clinical settings. A summary that mentions only the drug leaves out a central part of the approach being studied.

Three distinctions help preserve that meaning:

  • A research category is not a blanket treatment endorsement.
  • A named substance does not represent every related drug.
  • Clinical research does not justify unsupervised use.

This research area also should not be presented as proof that a powerful experience is itself a treatment mechanism. The overview does not establish that an experience outside clinical care reproduces what researchers are investigating.

You can be interested in the science without making a treatment decision based on it. The supported takeaway is that NIDA describes a combined, clinical research approach with continuing uncertainty, not a do-it-yourself method or a reason to interrupt established treatment.

How do addiction treatment research approaches differ from established treatments?

Established treatments have defined clinical roles, while emerging approaches are being investigated for additional roles. A proposed mechanism alone does not erase that distinction. Established addiction treatment science includes medication and behavioral care; Choice's Intensive Outpatient Program (IOP) describes weekly group and individual therapy, not an experimental-treatment offering.

NIDA's treatment and recovery explanation describes different purposes for established care. Some medicines address withdrawal or cravings. Behavioral therapies can help people change substance-related behaviors, respond to stress, and handle situations linked with use. These are connected tools, rather than competing explanations of addiction.

Different treatment targets and what they do not establish
ApproachTarget or purpose described by NIDABoundary to preserve
New or repurposed medicinesSubstance use, cravings, withdrawal, or related symptoms.An existing use for another condition does not establish an addiction indication.
Brain stimulationBrain circuitry involved in addiction and other disorders.Approval for smoking cessation does not establish other addiction uses.
Immune approachesRecruiting the immune system to keep drugs from entering the brain.A research target is not routine vaccination against addiction.
Psychedelic and dissociative researchPossible treatment roles with psychotherapy in clinical settings.The research description does not endorse unsupervised use.
Established medication and behavioral careDefined substance-specific and behavioral treatment needs.Care still needs to match the individual and the condition.

SAMHSA describes medication treatment as clinically driven and tailored to each person's needs. NIAAA likewise explains that there is no single alcohol-treatment approach that fits everyone. Established care does not mean one standard plan for every person.

Choice's IOP in Albuquerque, NM includes weekly group and individual therapy, learning about substance use disorder, and recovery tools. Its published program description does not establish access to any particular investigational approach or named medicine.

Research can expand future options while present care addresses current needs. For severe symptoms or immediate danger, call 911. For a mental health or substance use crisis, call or text 988, as described in NIDA's emergency guidance.

Frequently asked questions about addiction treatment research

Does NIDA studying a treatment mean it is already proven?

No. NIDA describes both established treatments and approaches still being studied. An entry in its research overview identifies an area of investigation, not proof that the approach is appropriate for routine care. The particular substance use disorder, treatment purpose, and clinical context still matter when interpreting a research description.

Are medications already approved for every substance use disorder?

No. NIDA describes approved medications for opioid use disorder, alcohol use disorder, and smoking cessation, while medicines for stimulant and cannabis use disorders remain research targets. The absence of an approved medicine does not mean there is no treatment. Behavioral therapies can address substance use and related recovery needs.

Does a smoking-cessation approval establish effectiveness for other addictions?

No. An approval concerns a particular treatment purpose; it does not automatically extend to other substance use disorders. NIDA identifies TMS as FDA-approved for smoking cessation while describing its use for other substance use disorders as an area of study. Those are different statements about the same technology.

Are addiction vaccines described by NIDA routine addiction treatment?

No. NIDA discusses vaccines and monoclonal antibodies within emerging treatment research. Their intended purpose is to recruit the immune system to keep drugs from entering the brain. That description does not establish routine vaccination against addiction, suitability for an individual, or a replacement for established medication and behavioral care.

Does psychedelic treatment research support unsupervised drug use?

No. NIDA describes psychedelic and dissociative drug research involving psychotherapy in clinical settings. That context does not establish that using a drug independently reproduces the approach being studied. A research description is not a recommendation to use a substance, stop prescribed treatment, or try to manage a substance use disorder alone.

Sources

If you're considering ongoing substance use care, you can review Choice's IOP and contact Choice Recovery Path when you're ready. A conversation can clarify current outpatient options and whether they may fit your needs. You don't have to choose a research approach before discussing support.

Accessibility tools

Choose the adjustments you need. Your choices are saved on this browser when storage is available.

Accessibility Statement